<div id="readability-page-1"><div> By Adriano Marchese <pre></pre> Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment. Shares traded 11% higher ahead of the morning bell at $2.18. The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. <pre></pre> Write to Adriano Marchese at adriano.marchese@wsj.com <pre></pre> (END) Dow Jones Newswires November 03, 2025 09:40 ET (14:40 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

Iovance生物治療

Iovance 生物治療的股票在盤前交易中上漲了 11%，至 2.18 美元，此前其癌症治療藥物 lifileucel 的第二階段試驗結果積極。約有 26% 的患者對該治療產生了反應，疾病控制率為 72%。該公司計劃在 2026 年發佈更多數據，並計劃明年向 FDA 提交生物製品許可申請，目標是在 2027 年下半年推出

Iovance 生物治療公司的股票在盤前交易中因其癌症藥物的積極試驗數據而上漲